Vesigen has attracted Leaps by Bayer to commercialise drug delivery technology invented by Quan Lu at Harvard School of Public Health.
Vesigen Therapeutics, a US-based precision medicine developer spun out of Harvard University, has emerged from stealth with $28.5m of series A funding co-led by Leaps by Bayer, an investment vehicle for drug and chemicals producer Bayer.
Morningside Ventures co-led the round, which also attracted Alexandria Venture Investments, the strategic investment arm of life sciences real estate investment trust Alexandria Real Estate Equities, and Linden Lake Ventures.
Vesigen Therapeutics is working toward drug candidates based on fusogenic extracellular vesicles,…
